Literature DB >> 3351608

Conjugate view gamma camera method for estimating tumor uptake of iodine-131 metaiodobenzylguanidine.

B L Shulkin1, J C Sisson, K F Koral, B Shapiro, X H Wang, J Johnson.   

Abstract

Therapy with [131I]MIBG has produced partial remissions of malignant pheochromocytomas but not all patients respond. Responses correlate with the quantity of radiation delivered. We developed the conjugate-view method of imaging using 131I reference sources of known radioactivity placed on the surface of the patient and standard nuclear medicine equipment (gamma camera and computer), to estimate tumor uptake of [131I]MIBG. Such an estimate is a first step toward calculating radiation absorbed dose. Three different methods of background subtraction were evaluated with an anthropomorphic phantom and in five patients. In phantom results, measured tumor activity decreased exponentially with a half-life in agreement with that of 131I to within 3%. However, in the phantom studies, in which non-tumor activity is zero, no single method of background subtraction is superior. In patients, two background subtraction methods, which take their estimate from regions immediately surrounding or adjacent to the tumor and reference source, are less sensitive to reference source position and appear more accurate than a third method which uses a background region of interest displaced from the tumor. The agreement of the calculated activity concentration (nCi/g) with that measured by counting portions of the excised tumors gives validation to the method.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3351608

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

2.  Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine.

Authors:  F A Khafagi; B Shapiro; M Fischer; J C Sisson; R Hutchinson; W H Beierwaltes
Journal:  Eur J Nucl Med       Date:  1991

3.  Multi-centre evaluation of accuracy and reproducibility of planar and SPECT image quantification: An IAEA phantom study.

Authors:  Brian E Zimmerman; Darko Grošev; Irène Buvat; Marco A Coca Pérez; Eric C Frey; Alan Green; Anchali Krisanachinda; Michael Lassmann; Michael Ljungberg; Lorena Pozzo; Kamila Afroj Quadir; Mariella A Terán Gretter; Johann Van Staden; Gian Luca Poli
Journal:  Z Med Phys       Date:  2016-04-19       Impact factor: 4.820

Review 4.  Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption.

Authors:  S E Strand; M Ljungberg; J Tennvall; K Norrgren; M Garkavij
Journal:  Med Biol Eng Comput       Date:  1994-09       Impact factor: 2.602

5.  Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG.

Authors:  Y Nakabeppu; M Nakajo
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

6.  The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience.

Authors:  L Troncone; V Rufini; P Montemaggi; F M Danza; A Lasorella; R Mastrangelo
Journal:  Eur J Nucl Med       Date:  1990

7.  Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma.

Authors:  Kenneth F Koral; John P Huberty; Bill Frame; Katherine K Matthay; John M Maris; Denise Regan; Daniel Normolle; Gregory A Yanik
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-06       Impact factor: 9.236

8.  Quantitative measurement of uptake of radiolabeled monoclonal antibody by means of planar data.

Authors:  Y Akiyama; N Yui; T Matsumoto; T A Iinuma; H Ikehira; H Fukuda; Y Tateno
Journal:  Ann Nucl Med       Date:  1991-03       Impact factor: 2.668

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.